Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
D,L-2-hydroxyglutaric aciduria is a rare inborn error of metabolism characterized by severe neonatal epileptic encephalopathy, episodes of apnea and respiratory distress, severe global developmental delay or absent psychomotor development, severe muscular hypotonia or absent voluntary movements, feeding difficulties and failure to thrive, absence of visual contact, abnormal brain morphology (including cerebral atrophy, ventriculomegaly and hypoplasia or dysplasia of the corpus callosum), mild dysmorphic features (frontal bossing, hypertelorism, downslanting palpebral fissures, flat nasal bridge), elevated CSF and plasma lactate and urinary Krebs cycle metabolites.
Features include always present findings: Seizure, Global developmental delay, Low muscle tone (hypotonia), and L-2-hydroxyglutaric aciduria; and very common findings: Increased urine alpha-ketoglutarate concentration and Increased urine succinate level. 23 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Encephalopathy, Seizure, Global developmental delay |
SLC25A1 function has not been fully characterized.
D,L-2-hydroxyglutaric aciduria is associated with mutations in the SLC25A1 gene on chromosome 22.
Genetic testing for SLC25A1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 4 always present features, 2 very common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE1. Research is primarily sponsored by academic and government institutions.
13 publications have been identified in PubMed for D,L-2-hydroxyglutaric aciduria. Research spans Case Report / Case Series (46%), Basic Science / Preclinical (23%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 46% |
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about D,L-2-hydroxyglutaric aciduria
Head and neck |
2 |
Microcephaly, Macrocephaly |
Digestive system | 2 | Feeding difficulties, Enlarged liver (hepatomegaly) |
Muscles | 2 | Severe muscular hypotonia, Low muscle tone (hypotonia) |
Lungs and breathing | 2 | Dyspnea, Difficulty breathing (respiratory insufficiency) |
Lab test results | 1 | Increased urine alpha-ketoglutarate concentration |
Eyes | 1 | Cerebral visual impairment |
Laboratory research | 3 | 23% |
Disease patterns and progression | 2 | 15% |
Research summaries | 1 | 8% |
New treatment approaches | 1 | 8% |
Lipiński P (2026). [PMID: 40380983](https://pubmed.ncbi.nlm.nih.gov/40380983/). *J Appl Genet*. [Review / Meta-Analysis]
Kasprzyk-Pawelec A (2025). [PMID: 39733217](https://pubmed.ncbi.nlm.nih.gov/39733217/). *Cell death and differentiation*. [Basic Science / Preclinical]
Engin Erdal A (2025). [PMID: 40660807](https://pubmed.ncbi.nlm.nih.gov/40660807/). *Journal of pediatric endocrinology & metabolism : JPEM*. [Epidemiology / Natural History]
Shimozato M (2025). [PMID: 39880652](https://pubmed.ncbi.nlm.nih.gov/39880652/). *Rinsho shinkeigaku = Clinical neurology*. [Case Report / Case Series]
Guo Q (2025). [PMID: 40870031](https://pubmed.ncbi.nlm.nih.gov/40870031/). *Genes*. [Case Report / Case Series]
Kasprzyk-Pawelec A (2024). [PMID: 37503155](https://pubmed.ncbi.nlm.nih.gov/37503155/). *bioRxiv*. [Basic Science / Preclinical]
Phua YL (2024). [PMID: 38772223](https://pubmed.ncbi.nlm.nih.gov/38772223/). *Molecular genetics and metabolism*. [Gene Therapy / Novel Therapeutics]
Rattanapornsompong K (2024). [PMID: 38305044](https://pubmed.ncbi.nlm.nih.gov/38305044/). *American journal of medical genetics. Part A*. [Case Report / Case Series]
Ding S (2024). [PMID: 38703293](https://pubmed.ncbi.nlm.nih.gov/38703293/). *Acta neurologica Belgica*. [Case Report / Case Series]
Fayed AI (2024). [PMID: 38795053](https://pubmed.ncbi.nlm.nih.gov/38795053/). *Neurocase*. [Case Report / Case Series]